Necrotizing enterocolitis (NEC) is a devastating inflammatory intestinal disease of premature infants in which breakdown of the epithelial barrier is central. Enteral lactadherin (milk fat globule-EGF factor 8), a breast-milk glycoprotein, protects the intestinal barrier in the neonatal rat NEC model, coinciding with normalization of junctional protein expression and relocalization of claudin-3, occludin, and E-cadherin to junctional membrane domains, but only correlatively. The source-faithful open problem left by that study, and unaddressed by the subsequent literature, is: by what causal molecular mechanism - interacting partners, signaling cascades, and intracellular trafficking pathways - does lactadherin relocalize junctional complexes and restore barrier integrity in NEC, and does the NEC-associated increase in junctional protein abundance reflect accelerated-but-immature postnatal barrier maturation or a compensatory-but-ineffective repair response?

Background

Necrotizing enterocolitis (NEC) is a severe, often fatal inflammatory disease of the intestine that primarily affects premature infants; destruction of the intestinal epithelial barrier - the single layer of cells that seals the gut lumen from the body, largely through intercellular junctions - is a central event in its pathogenesis. Two junction classes are decisive for this seal: tight junctions, multiprotein belts at the apical cell border whose constituents (the claudin family, occludin, and junctional adhesion molecule A, JAM-A) regulate paracellular permeability, and adherens junctions, mechanically anchoring complexes beneath them whose main adhesion molecule is E-cadherin. When these proteins are misplaced or misregulated, the barrier leaks and luminal bacteria and toxins drive the inflammatory cascade of NEC. Human milk strongly reduces NEC incidence, and one candidate protective component is lactadherin (also called milk fat globule-EGF factor 8, MFG-E8), a glycoprotein abundant in the milk fat globule membrane that binds phosphatidylserine (an outer-leaflet membrane lipid) and is reported to dampen inflammation, protect against rotavirus gastroenteritis, and modulate intestinal epithelial behavior. Shen, Lei, He, Liu and He (Journal of Cellular Biochemistry 2019, doi:10.1002/jcb.29255) tested recombinant human lactadherin given enterally at 10 micrograms per gram per day in an established neonatal rat NEC model: lactadherin reduced NEC incidence from 100% to 46.7%, reduced histological injury and intestinal permeability, and - unexpectedly - the ileal expression of the junctional proteins JAM-A, claudin-3, and E-cadherin was higher in NEC animals than in dam-fed controls and decreased with lactadherin, while lactadherin additionally changed the subcellular localization of claudin-3, occludin, and E-cadherin in epithelial cells. The authors concluded only tentatively that the mechanism of protection 'might be restoring the correct expression levels and localization of tight junction and adherent junction proteins'. This observation sits in a specific prior context: intestinal claudin-3 expression normally rises during postnatal barrier maturation over the first weeks of life, and commensal or probiotic bacteria can accelerate this maturation and stabilize claudins at tight junctions in experimental NEC (Patel et al. 2012, doi:10.1016/j.ajpath.2011.10.025; Bergmann et al. 2013, doi:10.1016/j.ajpath.2013.01.013). Whether a rise in junctional protein abundance in a diseased immature intestine therefore represents useful maturation or a futile compensatory repair response cannot be read off expression data alone, and the source study had no perturbation evidence connecting lactadherin to any receptor, signaling cascade, or trafficking route in enterocytes. The mechanism is stated only as a possibility, the counterintuitive junctional protein increase in NEC is the paper's own reported finding, and the work is confined to a rat model with no human dosing or safety data.

Problem Statement

In the established neonatal rat (or mouse) model of necrotizing enterocolitis, enteral recombinant lactadherin protects the intestinal epithelial barrier, and this protection coincides with normalization of junctional protein expression (JAM-A, claudin-3, E-cadherin) and relocalization of claudin-3, occludin, and E-cadherin to functional junctional membrane domains - but the evidence is correlative and the underlying process is unknown. The open problem, as posed by the source study and left unanswered by the subsequent literature, has two linked parts toward one objective - a causal account of how lactadherin protects the neonatal intestinal barrier in NEC: (1) By what molecular mechanism does lactadherin produce these effects - through which interacting partners or receptors on enterocytes (or immune cells), which signaling cascades, and which intracellular trafficking pathways that reposition claudin-3, occludin, and E-cadherin to the junctional complex? (2) Does the observed increase in junctional protein abundance in NEC represent an accelerated but immature postnatal barrier-maturation response or a compensatory but ineffective repair attempt, and through which arm of the proposed mechanism does lactadherin shift that balance toward functional junction maturation? A causal account requires perturbation-based (loss- and/or gain-of-function) evidence in an experimental neonatal NEC model that the proposed pathway is necessary and/or sufficient for both the junctional relocalization and the barrier-protective phenotype, and developmental and functional data adjudicating the maturation-versus-repair interpretation, which is settled by whether the abundance increase is coupled to functional sealing at the junction (an accelerated but immature maturation response) or uncoupled from barrier function (a compensatory but ineffective repair attempt), the two being distinguished by that functional coupling rather than treated as mutually exclusive. A rigorous demonstration that lactadherin's protection is not mediated by junctional relocalization at all is an admissible refuting answer to part (1), and by removing the mechanism arm it discharges the mechanism-dependent clause of part (2), leaving the developmental and functional characterization of the NEC abundance increase - the maturation-versus-repair question itself - to be supplied.

References

  1. Shen H, Lei Y, He X, Liu D, He Z. Role of lactadherin in intestinal barrier integrity in experimental neonatal necrotizing enterocolitis. Journal of Cellular Biochemistry 2019;120(12):19509-19517. doi:10.1002/jcb.29255, https://doi.org/10.1002/jcb.29255
  2. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. American Journal of Pathology 2012;180(2):626-635. doi:10.1016/j.ajpath.2011.10.025, https://doi.org/10.1016/j.ajpath.2011.10.025
  3. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li H, Chou PM, Weber CR, De Plaen IG. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. American Journal of Pathology 2013;182(5):1595-1606. doi:10.1016/j.ajpath.2013.01.013, https://doi.org/10.1016/j.ajpath.2013.01.013
  4. Xu R, Lei YH, Shi J, Zhou YJ, Chen YW, He ZJ. Effects of lactadherin on plasma D-lactic acid and small intestinal MUC2 and claudin-1 expression levels in rats with rotavirus-induced diarrhea. Experimental and Therapeutic Medicine 2016;11(3):943-950. doi:10.3892/etm.2016.3015, https://doi.org/10.3892/etm.2016.3015
  5. Nyegaard S, Andreasen T, Rasmussen JT. Lactadherin orthologs inhibit migration of human, porcine and murine intestinal epithelial cells. Food Science and Nutrition 2017;5(4):934-942. doi:10.1002/fsn3.479, https://doi.org/10.1002/fsn3.479
  6. Griffiths V, Al Assaf N, Khan R. Review of claudin proteins as potential biomarkers for necrotizing enterocolitis. Irish Journal of Medical Science 2021;190(4):1465-1472. doi:10.1007/s11845-020-02490-2, https://doi.org/10.1007/s11845-020-02490-2
  7. Asaro J, Khan Z, Brewer M, Klose K, Pesce C, Schanler RJ, Codipilly CN. Relationship between milk fat globule-epidermal growth factor 8 and intestinal cytokines in infants born preterm. Journal of Pediatrics 2021;230:71-75.e1. doi:10.1016/j.jpeds.2020.11.014, https://doi.org/10.1016/j.jpeds.2020.11.014
  8. Aziz M, Prince JM, Wang P. Gut microbiome and necrotizing enterocolitis: understanding the connection to find a cure. Cell Host and Microbe 2022;30(5):612-616. doi:10.1016/j.chom.2022.04.003, https://doi.org/10.1016/j.chom.2022.04.003
  9. Han D, Lu D, Huang S, Pang J, Wu Y, Hu J, Zhang X, Pi Y, Zhang G, Wang J. Small extracellular vesicles from Ptpn1-deficient macrophages alleviate intestinal inflammation by reprogramming macrophage polarization via lactadherin enrichment. Redox Biology 2022;58:102558. doi:10.1016/j.redox.2022.102558, https://doi.org/10.1016/j.redox.2022.102558
  10. Nofi CP, Prince JM, Brewer MR, Aziz M, Wang P. An anti-eCIRP strategy for necrotizing enterocolitis. Molecular Medicine 2024;30(1):156. doi:10.1186/s10020-024-00935-3, https://doi.org/10.1186/s10020-024-00935-3
  11. Garg PM, Denton MX, Ravisankar S, Herco M, Shenberger JS, Chen Y-H. Tight junction proteins and intestinal health in preterm infants. Journal of Neonatal-Perinatal Medicine 2025;18(5):409-418. doi:10.1177/19345798251349394, https://doi.org/10.1177/19345798251349394